败血症大鼠血浆白细胞介素8、肿瘤坏死因子及微循环变化  

Change of Plasma IL-8、TNF-α and Observation of Microcirculation on Sepsis in Rats

作　　者：刘凤[1] 于小玲[1] 石增立[1] 王宝娃[1] 董晓青[1] 赵子文[1] 

机构地区：[1]滨州医学院病理生理教研室,256603

出　　处：《中国微循环》1998年第4期211-213,共3页Journal of Chinese Microcirculation

摘　　要：目的：探讨败血症大鼠不同时间血浆白细胞介素（IL）8、肿瘤坏死因子α（TNF-α）和微循环变化及山莨菪碱（654－2）干预的影响。方法：采用盲肠结扎加穿刺法复制大鼠败血症模型，酶联免疫吸附试验检测血浆IL－8、TNF－α水平，WX－6型多部位微循环显微镜，观察微循环变化。结果：败血症组血浆IL－8、TNF－α水平随临床症状加重而增高，以实验后8小时增高较为显著；外周血白细胞数实验后0、8、16小时呈递减趋势，腹腔渗出液白细胞数则呈递增趋势。肠系膜及肠壁微循环严重紊乱，微动脉、微静脉明显扩张，血流缓慢，血细胞严重聚集，出血、渗出严重。654-2组上述两种细胞因子水平明显低于败血症组（P＜0．05），微循环障碍异常发生率明显低于败血症组（P＜0．01或0．05），动物存活率明显高于败血症组（P＜0．05）。结论：IL－8、TNF－α在败血症发生发展过程中可能起重要作用。654－2可能具有抑制IL－8、TNF－α过度产生或释放及改善微循环等作用。Objective:To detect the change of plasma IL-8、TNF-α and the microcirculation at different time,and to observe the effect of anisodamine (654-2) on sepsis in rats. Methods: The sepsis model of cecum ligate-puncture was used and levels of IL-8、TNF-α in plasma were measured using enzyme linked immunosorbent assay (ELISA),WX-6 type microcirculation microscope was used to observe the change of microcirculation in our study. Results: In sepsis group, levels of plasma IL-8、TNF-α were increased compared with severity of symptom and were very high in 8 hours postexperimentlly,and peripheral blood white cells count were reduced but the white cells count in abdominal cavity liquid raised in 0、8、16 hours postexperimentlly. Microcirculation disorders including arteriole and venule expanding,blood flowing retarding,blood cells aggregation,bleeding and severe exudation were observed in mesentery and intestinal canal. In anisodamine treating group,levels of IL-8、TNF-α and rate of microcirculation disorders reduced (P<0. 01 or 0. 05). and survival rate of rats increased compared with sepsis group(P<0. 05). Conclusions: IL-8 and TNF-α might play an important role in sepsis pathogenesis,and anisodamine might have the effects of inhibiting excess production or release of IL-8、TNF-α and imporving the microcirculation in sepsis.

关 键 词：IL-8 TNF 败血症 微循环 

分 类 号：R515.302[医药卫生—内科学]